Chemo after fully removed pancreatic cancer, guided by gene testing
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 study tests whether people with pancreatic cancer should get standard chemo or a chemo plan guided by a tumor gene/RNA test after surgery. It aims to see if the right chemo choice for your tumor biology can improve outcomes after your tumor is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed pancreatic ductal cancer (including variants) or pancreatic acinar cell cancer, found in tissue tested under a microscope.
- Your surgeon removed the tumor completely (R0 or R1), meaning no visible tumor remains; R2 (incomplete removal) usually does not qualify.
- You must have enough tissue from your surgery available for RNA testing (gene/RNA sequencing).
- You are between 18 and 79 years old and can do normal daily activities with little help (performance status 0–1).
- You have not had chemo or radiation for pancreatic cancer before, and you’ve fully recovered enough to eat well and take chemo without major uncontrolled nausea/vomiting.
- You must meet lab and health thresholds for blood counts, liver/bilirubin, and kidney function, and you must be free from distant spread (no metastases like fluid around lungs/abdomen).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
This study looks at blood samples to see if we can predict how well pancreatic cancer responds to chemotherapy before surgery. It aims to help doctors choose the best treatment for each patient.
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
This trial tests whether choosing chemotherapy based on a SMAD4 gene change in your tumor works better than the usual approach for pancreatic cancer that can be surgically removed. If you have the gene change, you may get a different chemotherapy combination to improve outcomes.
This trial tests whether giving different types of extra chemo (after surgery) based on the stage of your cancer can help prevent it from coming back. It's for people with pancreatic cancer who already had chemo and surgery.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.